Acute myeloid leukemia m2 low-risk group, the high or low cure rate can not be accurately determined, mainly with the age of onset and so on.
Acute myeloid leukemia m2 low-risk group is a low-risk partially differentiated acute granulocytic leukemia, often with a sudden onset of disease, usually after standardized treatment about 90% of children, 70% of young adults, 60% of middle-aged people, 25% of elderly patients, can be achieved complete remission.
The 5-year relative survival rate is 56% for those under 45 years of age, 39% for those between 45 and 54 years of age, and 27% for those between 55 and 64 years of age; the older the patient, the lower the 5-year survival rate. The overall median survival for AML m2 low-risk is lower due to the higher proportion of cases in older patients over 65 years of age. The remission rate with treatment decreases with increasing age at first diagnosis.
Patients in the acute myeloid leukemia m2 low-risk group are treated differently depending on their condition. Specific drugs include cytarabine and Zoerythromycin, etc. It is recommended to standardize the treatment under the guidance of the doctor for a speedy recovery.